University of Western Ontario
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1878-03-07
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.uwo.ca
GFAP Biomarker Analysis Shows Ozanimod's Impact on MS Disease Progression in ENLIGHTEN Trial
Interim analysis of ENLIGHTEN trial reveals ozanimod treatment reduced mean GFAP concentration from 115.0 to 103.2 pg/mL over one year in relapsing multiple sclerosis patients.
© Copyright 2025. All Rights Reserved by MedPath